A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, ...
"Our previous work showed that SARS-CoV-2 spike proteins lead to complement dysregulation by binding heparan sulfate and disrupting complement factor H…This doesn’t happen on red cells because red ...
4D Molecular Therapeutics (NASDAQ:FDMT) is acquiring worldwide rights to Aevitas Therapeutics' short-form human complement factor H (sCFH) asset for treating complement-mediated diseases. Under the ...
Among the most significant genetic risk factors for age-related macular degeneration is the Y402H variant of complement factor H, which, along with its splice isoform FHL-1, impairs binding to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results